ALLO · Why this verdict
Why Allogene Therapeutics (ALLO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Allogene has beaten earnings in 3 straight quarters, but sub-floor quality driven by cash burn and no moat, value-trap margin and leverage signals, justified elevated short interest, and a rejected, implausible analyst price target all argue for treating the stock's headline upside with skepticism.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Value-trap signals include -47.4% operating margin compression and elevated leverage at a D/E of 1.9, risking further capital erosion. Bear case | Operating margin should move toward breakeven for the value-trap concern to ease. | →Stable |
| CounterDeep operating margin compression is expected pre-revenue for a clinical-stage biotech and doesn't necessarily indicate a structurally broken business model. | ||
Allogene has beaten estimates in all 3 of its last reported quarters, with an average surprise of +19.5%, a proof point on execution despite quality concerns elsewhere. Earnings | The earnings beat streak should continue at the next report in 39 days for the execution thesis to strengthen. | ↓Deteriorating |
| CounterClinical-stage biotech earnings beats are often driven by expense timing rather than commercial progress, so the streak may not predict future results. | ||
Quality sits at 1.6, below the 4.0 floor, driven by negative free cash flow and no competitive moat, typical of a clinical-stage biotech burning cash. Quality breakdown | Quality score should improve if cash burn slows or a moat-building catalyst such as a partnership emerges. | →Stable |
| CounterPre-commercial cell-therapy biotechs are expected to burn cash while funding trials, so a low quality score may not reflect genuine business risk. | ||
The engine flags the stock's 15% short interest as justified given the underlying fundamentals, rather than a squeeze setup. Risk breakdown | Short interest should decline from 15% if the fundamental picture improves. | →Stable |
| CounterHigh short interest in a binary biotech name can still trigger a sharp squeeze on unexpected positive trial data regardless of whether it is fundamentally justified. | ||
The raw analyst price target was rejected as implausible at 4.1 times the current price, so the engine fell back to a technical take-profit, meaning the usual analyst-upside signal cannot be trusted here. Warnings | A revised, credible analyst target should emerge to restore confidence in the analyst-upside signal. | →Stable |
| CounterA stale or unadjusted analyst target following a major price decline is a data-lag issue, not necessarily evidence the original bullish view was wrong. | ||
Value-trap signals include -47.4% operating margin compression and elevated leverage at a D/E of 1.9, risking further capital erosion.
→StableBear case
- Expectation
- Operating margin should move toward breakeven for the value-trap concern to ease.
CounterDeep operating margin compression is expected pre-revenue for a clinical-stage biotech and doesn't necessarily indicate a structurally broken business model.
Allogene has beaten estimates in all 3 of its last reported quarters, with an average surprise of +19.5%, a proof point on execution despite quality concerns elsewhere.
↓DeterioratingEarnings
- Expectation
- The earnings beat streak should continue at the next report in 39 days for the execution thesis to strengthen.
CounterClinical-stage biotech earnings beats are often driven by expense timing rather than commercial progress, so the streak may not predict future results.
Quality sits at 1.6, below the 4.0 floor, driven by negative free cash flow and no competitive moat, typical of a clinical-stage biotech burning cash.
→StableQuality breakdown
- Expectation
- Quality score should improve if cash burn slows or a moat-building catalyst such as a partnership emerges.
CounterPre-commercial cell-therapy biotechs are expected to burn cash while funding trials, so a low quality score may not reflect genuine business risk.
The engine flags the stock's 15% short interest as justified given the underlying fundamentals, rather than a squeeze setup.
→StableRisk breakdown
- Expectation
- Short interest should decline from 15% if the fundamental picture improves.
CounterHigh short interest in a binary biotech name can still trigger a sharp squeeze on unexpected positive trial data regardless of whether it is fundamentally justified.
The raw analyst price target was rejected as implausible at 4.1 times the current price, so the engine fell back to a technical take-profit, meaning the usual analyst-upside signal cannot be trusted here.
→StableWarnings
- Expectation
- A revised, credible analyst target should emerge to restore confidence in the analyst-upside signal.
CounterA stale or unadjusted analyst target following a major price decline is a data-lag issue, not necessarily evidence the original bullish view was wrong.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -1368% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.2 |
| OBV | 10.0 |
| MA position | 2.2 |
| Volume | 6.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+0.1%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸Analyst upside: 592%
Insider
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider selling — $111,656 (0.025% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.1 |
| quality rank | 3.4 |
| growth rank | 5.0 |
Technical
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.4 |
| support resistance | 6.9 |
| 52w position | 0.0 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 1.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 9.6 |
| debt equity | 9.3 |
- ▸High short interest justified: 17%
- ▸Elevated put/call: 25.50
- ▸High IV: 110%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/0M
- ▸Earnings in 7 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- MOMENTUM:5.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:7d<=7d
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
13.0%
Sizing output
AVOID
SetupRange Bound — RSI 41 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -71% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 7d<=7d outcome against Catalyst at 7.0 and asymmetric R:R of 0.00.
The strongest dimensions are Catalyst at 7.0, Sentiment at 6.5, and Momentum at 5.9; the weakest are Quality at 1.8, Peer rank at 3.0, and Risk (lower is worse) at 3.1. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifAverage earnings surprise falls below 0% from the current +19.5%.
- P2Sub Floor Quality Cash Burn
Trip ifQuality score rises above 4.0 from the current 1.6.
- P3Value Trap Margin Leverage
Trip ifOperating margin rises above 0% from the current -47.4%.
- P4Justified Elevated Short Interest
Trip ifShort interest falls below 8% from the current 15%.
- P5Rejected Implausible Analyst Target
Trip ifA revised analyst target is published at less than 2x the current price, restoring analyst-target reliability.